Updated Data On Dendreon's (DNDN) Prostate Cancer Drug PROVENGE Shows Additional Survival Benefits
Tweet Send to a Friend
After the close, biotech company Dendreon (Nasdaq: DNDN) announced positive updated results from a Phase 3 trial of its prostate ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
